was read the article
array:24 [ "pii" => "S2253808922000945" "issn" => "22538089" "doi" => "10.1016/j.remnie.2022.09.005" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1389" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:3-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X22001044" "issn" => "2253654X" "doi" => "10.1016/j.remn.2022.06.005" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1389" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:3-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "La eficacia de [<span class="elsevierStyleSup">18</span>F]FDG PET/TC en el seguimiento de la progresión de la enfermedad en el mesotelioma pleural maligno" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "3" "paginaFinal" => "9" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The efficacy of [<span class="elsevierStyleSup">18</span>F]FDG PET/CT in monitoring disease progression in malignant pleural mesothelioma" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 942 "Ancho" => 3341 "Tamanyo" => 398804 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Un caso representativo de mesotelioma pleural maligno clasificado como progresión radiológica negativa según la TC y progresión metabólica positiva según PET/TC con [<span class="elsevierStyleSup">18</span>F]FDG. Se mostraron imágenes de la TC (AC) y de PET/TC con [<span class="elsevierStyleSup">18</span>F]FDG (G-I) al diagnóstico (fila superior) de un paciente varón de 63 años con MPM de tipo epitelioide. En el seguimiento de la progresión de la enfermedad debido a la sospecha clínica del paciente (fila inferior), la TC (D-F) mostró una regresión en los ganglios linfáticos mediastínicos, engrosamiento pleural y derrame pleural, la PET/TC con [<span class="elsevierStyleSup">18</span>F]FDG (J-L) mostró un aumento intenso de la captación de [<span class="elsevierStyleSup">18</span>F]FDG. La progresión radiológica del paciente fue negativa, pero la progresión metabólica fue positiva.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Y. Söyler, Ö. Özmen, P.A. Kabalak, H. Ertürk, F. Uğurman, Ü. Yılmaz" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Y." "apellidos" => "Söyler" ] 1 => array:2 [ "nombre" => "Ö." "apellidos" => "Özmen" ] 2 => array:2 [ "nombre" => "P.A." "apellidos" => "Kabalak" ] 3 => array:2 [ "nombre" => "H." "apellidos" => "Ertürk" ] 4 => array:2 [ "nombre" => "F." "apellidos" => "Uğurman" ] 5 => array:2 [ "nombre" => "Ü." "apellidos" => "Yılmaz" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808922000945" "doi" => "10.1016/j.remnie.2022.09.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922000945?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X22001044?idApp=UINPBA00004N" "url" => "/2253654X/0000004200000001/v1_202301180707/S2253654X22001044/v1_202301180707/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2253808922000830" "issn" => "22538089" "doi" => "10.1016/j.remnie.2022.08.003" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1381" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:10-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Is adipose tissue metabolic activity a predictor of pathological responses to neoadjuvant treatment in breast cancer" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "10" "paginaFinal" => "15" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Es la actividad metabólica del tejido adiposo un predictor de respuesta histopatológica del tratamiento neoadyuvante en cáncer de mama?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1030 "Ancho" => 3341 "Tamanyo" => 252624 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0045" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The measurements of activity parameters on PET/CT.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ozgecan Dulgar, Ebru Orsal Ibisoglu, Seval Ay, Hatice Uslu, Mahmut Gümüş" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Ozgecan" "apellidos" => "Dulgar" ] 1 => array:2 [ "nombre" => "Ebru Orsal" "apellidos" => "Ibisoglu" ] 2 => array:2 [ "nombre" => "Seval" "apellidos" => "Ay" ] 3 => array:2 [ "nombre" => "Hatice" "apellidos" => "Uslu" ] 4 => array:2 [ "nombre" => "Mahmut" "apellidos" => "Gümüş" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X22000725" "doi" => "10.1016/j.remn.2022.05.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X22000725?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922000830?idApp=UINPBA00004N" "url" => "/22538089/0000004200000001/v1_202301120623/S2253808922000830/v1_202301120623/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2253808922001185" "issn" => "22538089" "doi" => "10.1016/j.remnie.2022.12.002" "estado" => "S300" "fechaPublicacion" => "2023-01-01" "aid" => "1414" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "edi" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:1-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "SEMNIM has a plan and is counting on you" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "2" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La SEMNIM tiene un plan y cuenta contigo" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "María José García Velloso, Diego Becerra García, Cristina Peña, Ricardo Ruano Pérez, Iratxe Fernández, Adolfo Gómez, Mercedes Mitjavila, José Manuel Cordero, Edel Noriega" "autores" => array:9 [ 0 => array:2 [ "nombre" => "María José García" "apellidos" => "Velloso" ] 1 => array:2 [ "nombre" => "Diego Becerra" "apellidos" => "García" ] 2 => array:2 [ "nombre" => "Cristina" "apellidos" => "Peña" ] 3 => array:2 [ "nombre" => "Ricardo Ruano" "apellidos" => "Pérez" ] 4 => array:2 [ "nombre" => "Iratxe" "apellidos" => "Fernández" ] 5 => array:2 [ "nombre" => "Adolfo" "apellidos" => "Gómez" ] 6 => array:2 [ "nombre" => "Mercedes" "apellidos" => "Mitjavila" ] 7 => array:2 [ "nombre" => "José" "apellidos" => "Manuel Cordero" ] 8 => array:2 [ "nombre" => "Edel" "apellidos" => "Noriega" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922001185?idApp=UINPBA00004N" "url" => "/22538089/0000004200000001/v1_202301120623/S2253808922001185/v1_202301120623/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "The efficacy of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring disease progression in malignant pleural mesothelioma" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "3" "paginaFinal" => "9" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Yasemin Söyler, Özlem Özmen, Pınar Akın Kabalak, Hakan Ertürk, Feza Uğurman, Ülkü Yılmaz" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Yasemin" "apellidos" => "Söyler" "email" => array:1 [ 0 => "dryaseminsoyler@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:4 [ "nombre" => "Özlem" "apellidos" => "Özmen" "email" => array:1 [ 0 => "ozmenozlem@yahoo.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:4 [ "nombre" => "Pınar Akın" "apellidos" => "Kabalak" "email" => array:1 [ 0 => "pinarakinn@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:4 [ "nombre" => "Hakan" "apellidos" => "Ertürk" "email" => array:1 [ 0 => "ert.hakan@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:4 [ "nombre" => "Feza" "apellidos" => "Uğurman" "email" => array:1 [ 0 => "fugurman@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:4 [ "nombre" => "Ülkü" "apellidos" => "Yılmaz" "email" => array:1 [ 0 => "ulkuylmzdr@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Chest Diseases, Ankara Kecioren Sanatorium Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Nuclear Medicine, Ankara Kecioren Sanatorium Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Radiology, Ankara Kecioren Sanatorium Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La eficacia de 18F-FDG PET/CT en el seguimiento de la progresión de la enfermedad en el mesotelioma pleural maligno" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 972 "Ancho" => 3341 "Tamanyo" => 139690 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier overall survival analysis.</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">(A) Cumulative, (B) Metabolic progression positive versus metabolic progression negative according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT, (C) Radiologic progression positive versus radiologic progression negative according to CT.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Malignant pleural mesothelioma (MPM), which originates from pleural mesothelial cells, is a rare and highly aggressive primary pleural malignancy. The worldwide incidence of MPM is predicted to rise continuously in the next years due to the ongoing exposure to occupational or environmental asbestosis.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–4</span></a> The initial symptoms of MPM including dyspnea, chest pain, weight loss or a combination of these, are generally vague.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The lack of specific clinical manifestations and the paucity of effective diagnostic tools causes delayed diagnosis and leads to poor prognosis.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a> Furthermore, a previous study has shown recurrence rate of 75% even after multimodality treatment for MPM.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Its increasing incidence rate and poor prognosis will presumably make MPM one of the most lethal tumours with low survival rate (5-year survival rate of ≤5%) in the near future.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Early diagnosis, accurate staging and appropriate treatment decision is vital to manage patients with MPM. Not only these principles but also follow-up is important in MPM management.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> 3–4 monthly routine appointments with clinicians or a periodic radiologic assessment at 3–6 month intervals can be suggested in addition to clinical follow-up.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,9</span></a> The occurrence of signs and symptoms in patients during clinical follow-up should be an indication of disease progression for clinicians. In the event of suspicion of disease progression, CT scan is also considered.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Considering that MPM is a three-dimensional, heterogeneous, asymmetrical and non-spherical tumour, monitoring with a bi-dimensional method may be insufficient in determining real tumour extension or tumour shrinkage.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10–13</span></a> Recent studies have shown that <span class="elsevierStyleSup">18</span>F-FDG PET/CT can be an alternative method by showing the real tumour burden.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> With this in mind, the main aim of our study was to evaluate the efficacy of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring disease progression in MPM by comparing it with CT. Furthermore, we analysed the predictive role of <span class="elsevierStyleSup">18</span>F-FDG PET/CT and CT in the median overall survival (OS) in MPM patients.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material and method</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patients</span><p id="par0015" class="elsevierStylePara elsevierViewall">Patients with histologically proven MPM, who completed the scheduled initial treatment, from March 2009 to February 2020 in a tertiary referral hospital were reviewed retrospectively. The initial treatments were decided by an expert multidisciplinary cancer board of our hospital according to guidelines. A total of 71 patients who had both baseline (before treatment) <span class="elsevierStyleSup">18</span>F-FDG PET/CT and CT scans and, had both <span class="elsevierStyleSup">18</span>F-FDG PET/CT and CT scans for monitoring disease progression due to clinical suspicion during clinical follow up were enrolled. Patients (1) who did not receive any treatments for MPM due to medical reasons or self-refusal (n = 3), (2) whose radiologic or metabolic evaluation was considered as unreliable due to history of talc pleurodesis (n = 4), (3) who had radical surgery procedures (extra pleural pneumonectomy) (n = 6), (4) whose clinical information could not be reached (n = 2) were excluded. Finally, fifty-six patients were analysed.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Progression status according to CT [as radiologic progression negative (RPN) and radiologic progression positive (RPP)] and according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT [as metabolic progression negative (MPN) and metabolic progression positive (MPP)] were evaluated and the discrepancies between two methods were analysed. The flowchart of study population is shown in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">Electronic medical record systems of our hospital and patients’ files were used to obtain all imaging reports and clinical data. Recorded parameters included demographic data (age, gender), histologic subtype (epithelioid/non-epithelioid), disease stage (classified in accordance with the 8th edition of TNM staging system<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a>), history of talc pleurodesis, history of treatment, radiological and metabolic findings [location of tumour, pleural thickness pattern, diameter of pleural thickness (mm) measured from the thickest region of the pleura, mediastinal lymph-node involvement, restriction on lung volume and tumour maximum standardized uptake value (SUVmax), Δ SUVmax].</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Imaging protocols</span><p id="par0030" class="elsevierStylePara elsevierViewall">CT scans were performed in a supine position using 16-detector-row CT scanner AlexionTM (Toshiba; Otawara, Japan) with the following parameters: 120 kV, 150 mA, 1 mm slice thickness, 0.75 s rotation time, and 1.438 collimation beam pitch or 128-multidetector-row CT scanner (Ingenuity CT, Philips Healthcare, Andover, MA, USA) with the following parameters: 120 kV, 160 mA, 1,5 mm slice thickness, 0.5 s rotation time, and 64 × 0.625 collimation beam pitch. Iodinated contrast material, if used, at an infusion flow rate of 3−4 ml/s was administered intravenously using a power injector.</p><p id="par0035" class="elsevierStylePara elsevierViewall">PET/CT scans were obtained 60 min after intravenous injection of 370–555 Mbq (10−15 mCi) FDG with Siemens Biograph 6 HI-REZ integrated PET/CT scanner (Siemens Medical Solutions, Knoxville, TN, USA). FDG injection was administered to patients who confirmed that their blood glucose level was less than 150 mg/dL after 6 h of fasting. CareDose (Siemens) CT images were acquired with 130 kV, automatic, real-time dose modulation amperage, and slice thickness of 5 mm. Right after the CT scan, PET data were obtained for 3 min per bed position for a total of 6–8 bed positions. The CT data were used for attenuation correction. PET images were reconstructed using ordered subsets expectation maximization algorithm with four iterations, eight subsets and a Gaussian post-filtering with a trans-axial spatial resolution of 5 mm at full width at half maximum. After the reconstruction of the images, SUVmax was obtained for semi quantitative analysis of FDG uptake. SUVmax corrected for body weight was computed by standard methods from the activity in the most intense voxel in the three-dimensional tumour region from the trans-axial whole body images on attenuation-corrected PET/CT images.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Progression status according to CT</span><p id="par0040" class="elsevierStylePara elsevierViewall">A 25% increase in total tumour measurement or the appearance of one or more new lesions [progressive radiologic disease (PRD)] was defined as ‘radiologic progression positive (RPP)’. The disappearance tumour lesions [complete radiologic regression (CRR)] and a 25% decrease in the total tumour measurement [partial radiologic regression (PRR)] and no change in total tumour measurements or the presence of changes in total tumour measurements that did not meet the criteria of progression [stable radiologic disease (SRD)] was defined as ‘radiologic progression negative (RPN)’.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,12,15,16</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Progression status according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT</span><p id="par0045" class="elsevierStylePara elsevierViewall">A ≥25% increase in SUVmax (compared with the previous value) or abnormal <span class="elsevierStyleSup">18</span>F-FDG uptake in another location [progressive metabolic disease (PMD)] was defined as ‘metabolic progression positive (MPP)’. The complete resolution of abnormal <span class="elsevierStyleSup">18</span>F-FDG uptake on PET [complete metabolic regression (CMR)] and a ≥25% decrease in SUVmax (compared with the previous value) [partial metabolic regression (PMR)] and no change in <span class="elsevierStyleSup">18</span>F-FDG uptake on PET or the presence of changes in <span class="elsevierStyleSup">18</span>F-FDG uptake on PET that did not meet the criteria of progression [stable metabolic disease (SMD)] was defined as ‘metabolic progression negative (MPN)’.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,17</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Statistical analysis</span><p id="par0050" class="elsevierStylePara elsevierViewall">Statistical analyses were carried out with SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc. Chi-squared test was used to compare demographic data between RPN and RPP, and MPN and MPP. RPN and RPP were compared in terms of metabolic findings. Student-t test for parametric variables and chi-squared test for non-parametric variables were used. Data showing number/percent (%) of cases according to progression status types were given by using descriptive analyses. The concordance between CT and by <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring progression was calculated by Cohen's K coefficient. The median follow-up duration was calculated with reverse Kaplan–Meier method. The OS according to radiological or metabolic data were estimated by using the Kaplan–Meier method.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">IRB approval statement</span><p id="par0055" class="elsevierStylePara elsevierViewall">The study was approved by our hospital’s Medical Specialty Education Board (Decision no: 701, Date: 19.11.2020) was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was waived because of the retrospective nature of the study.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Results</span><p id="par0060" class="elsevierStylePara elsevierViewall">A total of fifty-six patients (21 females, 35 males) with histologically proven MPM met the inclusion criteria. All patients were grouped as RPN (n = 31, 55.5%) and RPP (n = 25, 44.6%) according to CT and, MPN (n = 26, 46.4%) and MPP (n = 31, 53.5%) according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT. Among all patients, the histological subtypes were epithelioid (n = 49, 87.5%) and non-epithelioid (biphasic, sarcomatoid or not otherwise specified) (n = 7, 12.5%). In accordance with the 8th edition of TNM staging system, 24 (43%) were stage I, 9 (16%) were stage II, 20 (36%) were stage III, and 3 (5%) were stage IV. Forty-five patients (80%) received only chemotherapy while the remaining 11 patients received bimodal treatment (n = 9) (chemotherapy ± pleurectomy/decortication or partial pleurectomy) or trimodal treatment (n = 2) (chemotherapy + pleurectomy/decortication or partial pleurectomy + radiotherapy). The most determined pleural thickness pattern was diffuse pattern (n = 29, 46%) and the diameter of pleural thickness was 15.1 ± 10.4 mm. There were no significant differences in terms of general characteristics (age, sex, histologic subtype, diseases stage, history of pleurodesis), and radiological findings (location of tumour, pleural thickness pattern, diameter of pleural thickness) according to both CT groups and <span class="elsevierStyleSup">18</span>F-FDG PET/CT groups (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">The baseline and follow-up <span class="elsevierStyleSup">18</span>F-FDG PET/CT was evaluated, tumour SUVmax and Δ SUVmax were compared between RPN and RPP. The baseline tumour SUVmax was 7.3 ± 3.7 in all patients (7.7 ± 4.1 in RPN vs. 6.9 ± 3.1 in RPP, p = 0.41). According to the follow-up <span class="elsevierStyleSup">18</span>F-FDG PET/CT, tumour SUVmax was 8.1 ± 5.8 in all patients (5.1 ± 3.5 in RPN vs. 11.8 ± 6.1 in RPP, p < 0.001). Δ SUVmax was -2.5 ± 4.2 in RPN and 4.8 ± 6. in RPP (p < 0.001).</p><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">The discrepancies and concordance between CT and <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring disease progression</span><p id="par0070" class="elsevierStylePara elsevierViewall">As mentioned above, thirty-one (55.3%) patients were RPN [PRR (n = 26, 46.4%) and SRD (n = 5, 8.9%)] and 25 (44.6%) were RPP according to CT, while twenty-six (46.4%) patients were MPN [PMR (n = 22, 39.2%) and SMD (n = 4, 7.1%)] and 30 (53.5%) were MPP according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). Among all RPN, 26 patients were found to be MPN. In other words, all RPP patients were also found to be MPP, however, among RPN patients, 5 (8.9% of all patients) were evaluated as MPP (or PMD) on <span class="elsevierStyleSup">18</span>F-FDG PET/CT (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>) A representative <span class="elsevierStyleSup">18</span>F-FDG-PET/CT and CT images of a patient classified as RPN who was actually MPP is shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>. Furthermore, the concordance between CT and <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring disease progression was very good (K = 0.423; p < 0.01).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Survival analysis</span><p id="par0075" class="elsevierStylePara elsevierViewall">The median follow-up duration was 79 (range; 8.4–126) months. At the time of analysis, 36 (64%) patients were dead. The median OS was 26 ± 2.6 months in all patients. The median OS in RPN was 28.2 ± 4.6 months, while in RPP was 24.3 ± 3.1 months (p = 0.56). The median OS in MPN was 21.9 ± 2.5 months, while in MPP was 28.1 ± 3.7 months (p = 0.25) (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Discussion</span><p id="par0080" class="elsevierStylePara elsevierViewall">Due to unique patterns of growth and anatomic reasons such as the curved structure of the thoracic wall, initial assessment and follow-up of MPM may pose challenges.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,11,16</span></a> In this regard, we sought to evaluate the efficacy of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring disease progression in MPM by comparing it with CT. Our results have demonstrated very good concordance in progression status assessment between two methods, even though <span class="elsevierStyleSup">18</span>F-FDG PET/CT detected more progression than CT did. On the other hand, the OS has shown no correlation between groups according to both methods.</p><p id="par0085" class="elsevierStylePara elsevierViewall">Beyond the measurement of the morphological data, PET/CT is used as a comprehensive method that evaluate metabolic data and their responses to treatments in oncological patients.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> Until now, tumour SUVmax has been considered as an independent prognostic factor in MPM.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,12,19,20</span></a> Additionally, its increased value was related to advanced stage, histological subtypes with poor prognosis (non-epithelioid histology) and recurrent MPM.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,15</span></a> In our study, tumour SUVmax, which was similar in both groups before treatment, was found to be higher in radiologic non-responders group after treatment, as expected. In line with this, ΔSUVmax was also significantly higher in this group. This result thus substantiates the usefulness of SUVmax and ΔSUVmax in the follow-up and outcome prediction in MPM, which has been proved by previous studies.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,21</span></a> However, Schaefer et al. has suggested that due to ongoing morphological response in MPM over time, evaluations after treatment should be based on progression in CT not SUVmax.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Considering MPM is not generally a curable cancer, the follow-up strategies are important to monitor disease progression, preclude redundant aggressive therapy, reduce toxicity from ineffective chemotherapy, and guide decision of an alternative treatment option. Guidelines, however, state that PET/CT is still under investigation for follow-up, and is not validated in MPM.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,9</span></a> They hypothesized that FDG uptake and SUVmax measurements may be affected by several reasons. The presence of an inflammatory response such as previous chemical pleurodesis or parapneumonic effusions, may be causes of false positives. Besides, small volume tumours or early stage epithelioid mesothelioma in which FDG uptake is low, and postoperative settings may lead to misinterpretation.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,9,10</span></a> On the other hand, there have been a number of studies suggesting that <span class="elsevierStyleSup">18</span>F-FDG PET/CT may be useful in this regard. In Kitajima et al.’s study that assessed the clinical utility of PET/CT after surgery in MPM, it has been shown that PET/CT resulted in a change of management in 28% of patients, and detected recurrence in 12% of patients with no recurrence on contrast-enhanced CT.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> The previous studies by Kanemura et al. and Kitajima et al., and our study reached similar results that demonstrate the discrepancies between PET/CT and CT.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,24</span></a> These may be explained by the better capability of <span class="elsevierStyleSup">18</span>F-FDG PET/CT to detect conditions such as local progression, lymph node involvement or distant metastasis. Another possible reason of this discrepancy is limitation of CT including the underestimation of the presence of local tumour invasion into the adjacent chest wall, diaphragm and pericardium or the failure of detection of lymph node metastasis.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,25,26</span></a> In our study, two methods had very good concordance with each other, even though <span class="elsevierStyleSup">18</span>F-FDG PET/CT detected more progression than CT did. However, it should also be noted that there were no other confirmation methods for <span class="elsevierStyleSup">18</span>F-FDG PET/CT and CT results. On the other hand, <span class="elsevierStyleSup">18</span>F-FDG PET/CT is an expensive, time consuming and less accessible method. Thus, CT, due to being time- and cost-efficient and also easier accessibility, may be used as an initial step by determining whether there is a progression or not, and which patients need to undergo <span class="elsevierStyleSup">18</span>F-FDG PET/CT.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Because there is no need for further evaluation, if CT can detect progression. Nevertheless, <span class="elsevierStyleSup">18</span>F-FDG PET/CT may be used in the event of suspicion of disease progression even if it is not detected on CT.</p><p id="par0095" class="elsevierStylePara elsevierViewall">The median OS is approximately 6–9 months in untreated MPM patients and varies from 9.4–29 months despite the advantages in treatment options.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,20,25,27</span></a> Increasing age, male sex, advanced stage, non-epithelioid histology, and poorer performance status are prognostic of worse OS.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> We observed slightly longer median OS with respect to those reported in the literature. However, it cannot be ruled out that our study population characteristics or a reference time point which survival times were measured (it was the date of diagnosis in our study) may have influenced this result.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> For instance, the mean age and the number of patients with advanced stage is low, and the number of patients with epithelioid histology is high in our study.</p><p id="par0100" class="elsevierStylePara elsevierViewall">In the estimation of OS between patients with progression and without progression, neither CT nor <span class="elsevierStyleSup">18</span>F-FDG PET/CT showed any difference. This is consistent with Asabella et al.’s results.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> There were also a number of studies in the literature which were incompatible with our results. Schaefer et al. has reported that radiologic evaluation showed higher correlation than metabolic evaluation, while Ceresoli et al. has showed longer OS in metabolic responders.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,28</span></a> Kanemura et al. has demonstrated that metabolic responders’ OS was longer, even though there were no significant difference.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Interestingly, MPP had longer OS in our study, but this did not reach significant difference. The different results between various studies, including ours, may be explained by the studies’ small sample size, false positive of FDG or biological differences of MPM patients who enrolled into the studies.</p><p id="par0105" class="elsevierStylePara elsevierViewall">Our study has some limitations. This is a retrospective and single-institution study. However, our hospital is one of the reference institutions for patients with MPM in our country. Our study may be limited by the small sample size and heterogeneous population due to the rarity of MPM. Lastly, it can be thought that there may be a doubt related to FDG uptake in patients with talc pleurodesis. However, <span class="elsevierStyleSup">18</span>F-FDG PET/CT data were evaluated carefully by comparing the areas of FDG uptake due to MPM with baseline <span class="elsevierStyleSup">18</span>F-FDG PET/CT. Additionally, patients for whom a reliable interpretation could not be made due to talc pleurodesis were not included in the study.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conclusion</span><p id="par0110" class="elsevierStylePara elsevierViewall">Taken together, our results suggest that both methods are equally acceptable in monitoring disease progression in MPM, even though <span class="elsevierStyleSup">18</span>F-FDG PET/CT detected more progression than CT did. It is clear that large-scale, prospective, multi-center studies are required in order to elucidate this topic and also confirm or refute our results. Hopefully, more research into this regard will provide insight into which method is the most accurate for the follow-up of patients with MPM.</p></span><span id="sec1070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Funding</span><p id="par0115" class="elsevierStylePara elsevierViewall">This research did not receive any specific grant.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect8130">Conflict of interest</span><p id="par5115" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Author contributions</span><p id="par0120" class="elsevierStylePara elsevierViewall">All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres1831609" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Materials and Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1596677" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1831610" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Materiales y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1596678" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and method" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Patients" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Imaging protocols" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Progression status according to CT" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Progression status according to F-FDG PET/CT" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Statistical analysis" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "IRB approval statement" ] ] ] 6 => array:3 [ "identificador" => "sec0045" "titulo" => "Results" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "The discrepancies and concordance between CT and F-FDG PET/CT in monitoring disease progression" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Survival analysis" ] ] ] 7 => array:2 [ "identificador" => "sec0060" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0065" "titulo" => "Conclusion" ] 9 => array:2 [ "identificador" => "sec1070" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflict of interest" ] 11 => array:2 [ "identificador" => "sec0075" "titulo" => "Author contributions" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1596677" "palabras" => array:4 [ 0 => "Computed tomography" 1 => "Follow-up strategies" 2 => "Malignant pleural mesothelioma (MPM)" 3 => "Tumour SUVmax <span class="elsevierStyleSup">18</span>F-FDG PET/CT" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1596678" "palabras" => array:5 [ 0 => "Estrategias de seguimiento" 1 => "Mesotelioma pleural maligno (MPM)" 2 => "SUVmáx tumoral" 3 => "PET/TC con<span class="elsevierStyleSup">18</span>F-FDG" 4 => "Tomografía computarizada" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">In the event of suspicion of malignant pleural mesothelioma (MPM) progression, imaging plays an important role. We aimed to evaluate the efficacy of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in monitoring disease progression by comparing it with CT, and estimate median overall survival (OS) according to progression status with CT and <span class="elsevierStyleSup">18</span>F-FDG PET/CT.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Materials and Methods</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">This was an observational, retrospective, single-institution study with MPM patients who had both <span class="elsevierStyleSup">18</span>F-FDG PET/CT and CT for monitoring disease progression from March 2009 to February 2020. Clinical features, radiological findings, and progression status according to CT [radiologic progression negative (RPN), radiologic progression positive (RPP)] and <span class="elsevierStyleSup">18</span>F-FDG PET/CT [metabolic progression negative (MPN), metabolic progression positive (MPP)] were recorded. The discrepancies and concordance between two methods were evaluated. The OS was estimated using the Kaplan–Meier method.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">A total of 56 patients were included. There were thirty-one (55.3%) RPN and 25 (44.7%) RPP, while there were 26 (46.5%) MPN and 30 (53.5%) MPP. All RPP patients were also found to be MPP, however, among RPN, 5 patients (8.9% of all patients) were evaluated as MPP. The concordance between two methods in monitoring disease progression was very good (K = 0.423; p < 0.01). The OS was 26 ± 2.6 months in all patients. Kaplan-Meier curves between RPN and RPP, and between MPN and MPP did not show statistically significant differences (p = 0.56 and p = 0.25, respectively).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Both methods are equally acceptable in monitoring disease progression in MPM, even though <span class="elsevierStyleSup">18</span>F-FDG PET/CT detected more progression than CT did.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Materials and Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">En caso de sospecha de progresión del mesotelioma pleural maligno (MPM), la imagen juega un papel importante. Nuestro objetivo es evaluar la eficacia de la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG en el seguimiento de la progresión de la enfermedad, comparándola con la TC, y estimar la mediana de supervivencia global (SG) según el estado de progresión con la TC y la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Materiales y métodos</span><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Se trata de un estudio observacional, retrospectivo y monocéntrico con pacientes con MPM a los que se les realizó tanto PET/CT con <span class="elsevierStyleSup">18</span>F-FDG como TC para controlar la progresión de la enfermedad desde marzo de 2009 hasta febrero de 2020. Se registraron las características clínicas, los hallazgos radiológicos y el estado de progresión según la TC [progresión radiológica negativa (PRN), progresión radiológica positiva (PRP)] y la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG [progresión metabólica negativa (PMN), progresión metabólica positiva (PMP)]. Se evaluaron las discrepancias y la concordancia entre ambos métodos. La SG se estimó mediante el método de Kaplan–Meier.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Se incluyeron un total de 56 pacientes. Había 31 (55,3%) PRN y 25 (44.7%) PRP, mientras que había 26 (46.5%) PMN y 30 (53.5%) PMP. Todos los pacientes con PRP también resultaron ser PMP, sin embargo, entre los PRN, 5 pacientes (8.9% de todos los pacientes) fueron evaluados como PMP. La concordancia entre los dos métodos en el seguimiento de la progresión de la enfermedad fue muy buena (K = 0.423; p < 0.01). La SG fue de 26 ± 2.6 meses en todos los pacientes. Las curvas de Kaplan-Meier entre PRN y PRP, y entre PMN y PMP no mostraron diferencias estadísticamente significativas (p = 0.56 y p = 0.25, respectivamente).</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Ambos métodos son igualmente aceptables en el seguimiento de la progresión de la enfermedad en el MPM, aunque la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG detectó más progresión que la TC.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Materiales y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "multimedia" => array:5 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1833 "Ancho" => 3333 "Tamanyo" => 659847 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The flowchart of study population.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 942 "Ancho" => 3341 "Tamanyo" => 398048 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A representative case of malignant pleural mesothelioma classified as radiologic progression negative according to CT and metabolic progression positive according to <span class="elsevierStyleSup">18</span>F-FDG-PET/CT. CT (A-B-C) and <span class="elsevierStyleSup">18</span>F-FDG-PET/CT (G-H-I) images at baseline (upper row) of a 63-year-old male patient with epithelioid type MPM were shown. In monitoring disease progression due to clinical suspicion of the patient (lower row), CT (D-E-F) showed a regression in mediastinal lymph nodes, pleural thickening and pleural effusion, <span class="elsevierStyleSup">18</span>F-FDG-PET/CT (J-K-L) showed an intensely increased <span class="elsevierStyleSup">18</span>F-FDG uptake. The patient's radiological progression was negative but metabolic progression was positive.</p>" ] ] 2 => array:8 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 972 "Ancho" => 3341 "Tamanyo" => 139690 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier overall survival analysis.</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">(A) Cumulative, (B) Metabolic progression positive versus metabolic progression negative according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT, (C) Radiologic progression positive versus radiologic progression negative according to CT.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0020" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">MPN, metabolic progression negative; MPP, metabolic progression positive; RPN, radiologic progression negative; RPP, radiologic progression positive.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Variables \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RPN (n = 31) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RPP (n = 25) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p value \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">MPN (n = 26) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">MPP (n = 30) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">General characteristics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.1 ± 12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.6 ± 12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59 ± 12.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.6 ± 11.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.85 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female/Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11/20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10/15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.72 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10/16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11/19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.89 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Histologic subtype \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Epithelioid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.54 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Non-epithelioid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TNM stage<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.26 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Talc pleurodesis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.24 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bi-modal<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.02 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.02 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tri-modal<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Radiologic findings \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Location of tumour \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Left hemithorax \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.61 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.41 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Right hemithorax \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pleural thickness pattern \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diffuse \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Nodular \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.68 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.95 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mix \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diameter of pleural thickness (mm) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16.4 ± 11.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14.2 ± 9.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15.6 ± 11.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15.3 ± 9.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.93 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">8th edition of TNM staging system.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Bi-modal: Surgery + Chemotherapy.</p>" ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Tri-modal: Surgery + Chemotherapy + Radiotherapy.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">General characteristics and radiologic findings of study population.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0025" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">PMD, progressive metabolic disease; PMR, partial metabolic regression; PRD, progressive radiologic disease; PRR, partial radiologic regression; SMD, stable metabolic disease; SRD, stable radiologic disease.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " rowspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"></th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " rowspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"></th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " rowspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"></th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a>F-FDG PET/CT</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " rowspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Metabolic progression negative</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Metabolic progression positive \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PMR \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">SMD \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PMD \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CT</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Radiologic progression negative</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PRR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SRD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Radiologic progression positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PRD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">The discrepancies between <a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a>F-FDG PET/CT and CT findings in monitoring disease progression.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:28 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Scherpereel" 1 => "I. Opitz" 2 => "T. Berghmans" 3 => "I. Psallidas" 4 => "M. Glatzer" 5 => "D. Rigau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.00953-2019" "Revista" => array:4 [ "tituloSerie" => "Eur Respir J" "fecha" => "2020" "volumen" => "55" "numero" => "6" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Malignant pleural mesothelioma: between pragmatism and hope" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Migliore" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.21037/atm.2020.03.58" "Revista" => array:6 [ "tituloSerie" => "Ann Transl Med" "fecha" => "2020" "volumen" => "8" "numero" => "14" "paginaInicial" => "896" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32793740" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnostic imaging and workup of malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Cardinale" 1 => "F. Ardissone" 2 => "D. Gned" 3 => "N. Sverzellati" 4 => "E. Piacibello" 5 => "A. Veltri" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.23750/abm.v88i2.5558" "Revista" => array:7 [ "tituloSerie" => "Acta Biomed" "fecha" => "2017" "volumen" => "88" "numero" => "2" "paginaInicial" => "134" "paginaFinal" => "142" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28845826" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Pavic" 1 => "M. Bogowicz" 2 => "J. Kraft" 3 => "D. Vuong" 4 => "M. Mayinger" 5 => "S.G.C. Kroeze" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13550-020-00669-3" "Revista" => array:4 [ "tituloSerie" => "EJNMMI Res" "fecha" => "2020" "volumen" => "10" "numero" => "1" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multimodality treatment of malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Berzenji" 1 => "P. Van Schil" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.12688/f1000research.15796.1" "Revista" => array:4 [ "tituloSerie" => "F1000Res" "fecha" => "2018" "volumen" => "7" "itemHostRev" => array:3 [ "pii" => "S1529943007008984" "estado" => "S300" "issn" => "15299430" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and treatment of malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F.R. Panadero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3779/j.issn.1009-3419.2009.01.012" "Revista" => array:7 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2015" "volumen" => "51" "numero" => "4" "paginaInicial" => "177" "paginaFinal" => "184" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25059587" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "FDG PET/CT in the management of primary pleural tumors and pleural metastases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Kruse" 1 => "S.J. Sherry" 2 => "V. Paidpally" 3 => "G. Mercier" 4 => "R.M. Subramaniam" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2214/AJR.13.10572" "Revista" => array:6 [ "tituloSerie" => "Am J Roentgenol" "fecha" => "2013" "volumen" => "201" "numero" => "2" "paginaInicial" => "215" "paginaFinal" => "226" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.H. Baldini" 1 => "W.G. Richards" 2 => "R.R. Gill" 3 => "B.M. Goodman" 4 => "O.K. Winfrey" 5 => "H.M. Eisen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jtcvs.2014.10.128" "Revista" => array:6 [ "tituloSerie" => "J Thorac Cardiovasc Surg" "fecha" => "2015" "volumen" => "149" "numero" => "5" "paginaInicial" => "1374" "paginaFinal" => "1381" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Woolhouse" 1 => "L. Bishop" 2 => "L. Darlison" 3 => "D. De Fonseka" 4 => "A. Edey" 5 => "J. Edwards" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2017-211321" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2018" "volumen" => "73" "paginaInicial" => "i1" "paginaFinal" => "i30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29444986" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.G. Armato" 1 => "A.K. Nowak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jtho.2018.04.034" "Revista" => array:7 [ "tituloSerie" => "J Thorac Oncol." "fecha" => "2018" "volumen" => "13" "numero" => "7" "paginaInicial" => "1012" "paginaFinal" => "1021" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29753121" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Objective response rate assessment in oncology: current situation and future expectations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "N.F. Aykan" 1 => "T. Özatlı" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5306/wjco.v11.i2.53" "Revista" => array:7 [ "tituloSerie" => "World J Clin Oncol" "fecha" => "2020" "volumen" => "11" "numero" => "2" "paginaInicial" => "53" "paginaFinal" => "73" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32133275" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.N. Asabella" 1 => "A. Di Palo" 2 => "C. Altini" 3 => "M. Fanelli" 4 => "C. Ferrari" 5 => "V. Lavelli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1967/s002449910904" "Revista" => array:7 [ "tituloSerie" => "Hell J Nucl Med" "fecha" => "2018" "volumen" => "21" "numero" => "3" "paginaInicial" => "191" "paginaFinal" => "197" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30411729" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R. van Klaveren" 1 => "J. Aerts" 2 => "H. de Bruin" 3 => "G. Giaccone" 4 => "C. Manegold" 5 => "J. van Meerbeeck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0169-5002(03)00292-7" "Revista" => array:6 [ "tituloSerie" => "Lung Cancer" "fecha" => "2004" "volumen" => "43" "paginaInicial" => "63" "paginaFinal" => "69" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14698538" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V.W. Rusch" 1 => "K. Chansky" 2 => "H.L. Kindler" 3 => "A.K. Nowak" 4 => "H.I. Pass" 5 => "D.C. Rice" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jtho.2016.09.124" "Revista" => array:7 [ "tituloSerie" => "J Thorac Oncol" "fecha" => "2016" "volumen" => "11" "numero" => "12" "paginaInicial" => "2112" "paginaFinal" => "2119" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27687962" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Kanemura" 1 => "K. Kuribayashi" 2 => "N. Funaguchi" 3 => "E. Shibata" 4 => "K. Mikami" 5 => "H. Doi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejrad.2016.11.009" "Revista" => array:6 [ "tituloSerie" => "Eur J Radiol" "fecha" => "2017" "volumen" => "86" "paginaInicial" => "92" "paginaFinal" => "98" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28027772" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modified RECIST criteria for assessment of response in malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Bryne" 1 => "A. Nowak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdh059" "Revista" => array:7 [ "tituloSerie" => "Ann Oncol" "fecha" => "2004" "volumen" => "15" "numero" => "2" "paginaInicial" => "257" "paginaFinal" => "260" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14760119" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Ca" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Young" 1 => "R. Baum" 2 => "U. Cremerius" 3 => "K. Herholz" 4 => "O. Hoekstra" 5 => "A.A. Lammertsma" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0959-8049(99)00229-4" "Revista" => array:7 [ "tituloSerie" => "Eur J Cancer" "fecha" => "1999" "volumen" => "35" "numero" => "13" "paginaInicial" => "1773" "paginaFinal" => "1782" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10673991" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Unterrainer" 1 => "M. Ruzicka" 2 => "M.P. Fabritius" 3 => "L.M. Mittlmeier" 4 => "M. Winkelmann" 5 => "J. Rübenthaler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s41747-020-00190-1" "Revista" => array:7 [ "tituloSerie" => "Eur Radiol Exp" "fecha" => "2020" "volumen" => "4" "numero" => "1" "paginaInicial" => "1" "paginaFinal" => "13" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31900683" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleSup">18</span>F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.N. Asabella" 1 => "A. Notaristefano" 2 => "D. Rubini" 3 => "C. Altini" 4 => "C. Ferrari" 5 => "N. Merenda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clinimag.2013.06.009" "Revista" => array:7 [ "tituloSerie" => "Clin Imaging" "fecha" => "2013" "volumen" => "37" "numero" => "6" "paginaInicial" => "1098" "paginaFinal" => "1103" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23932389" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic value of SUVmax on <span class="elsevierStyleSup">18</span>F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.H. Lim" 1 => "J.Y. Choi" 2 => "Y. Im" 3 => "H. Yoo" 4 => "B.W. Jhun" 5 => "B.H. Jeong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0229299" "Revista" => array:6 [ "tituloSerie" => "PLoS One" "fecha" => "2020" "volumen" => "15" "numero" => "2" "paginaInicial" => "1" "paginaFinal" => "11" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Lopci" 1 => "P. Zucali" 2 => "G. Ceresoli" 3 => "M. Perrino" 4 => "L. Giordano" 5 => "L. Gianoncelli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-014-2960-y" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2015" "volumen" => "42" "paginaInicial" => "667" "paginaFinal" => "675" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25403555" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of <span class="elsevierStyleSup">18</span>F-FDG-PET/CT" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Schaefer" 1 => "P. Veit-Haibach" 2 => "J. Soyka" 3 => "H. Steinert" 4 => "R. Stadel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejrad.2010.11.006" "Revista" => array:7 [ "tituloSerie" => "Eur J Radiol" "fecha" => "2012" "volumen" => "81" "numero" => "1" "paginaInicial" => "e19" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21129871" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – comparison with contrast-enhanced CT" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kitajima" 1 => "M. Hashimoto" 2 => "T. Katsuura" 3 => "N. Kondo" 4 => "T. Minami" 5 => "K. Kuribayashi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18632/oncotarget.27324" "Revista" => array:7 [ "tituloSerie" => "Oncotarget" "fecha" => "2019" "volumen" => "10" "numero" => "63" "paginaInicial" => "6816" "paginaFinal" => "6828" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31827724" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to immune checkpoint inhibitor therapy in patients with unresectable recurrent malignant pleural mesothelioma shown by FDG-PET and CT" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kitajima" 1 => "M. Maruyama" 2 => "H. Yokoyama" 3 => "T. Minami" 4 => "T. Yokoi" 5 => "A. Nakamura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/cancers13051098" "Revista" => array:4 [ "tituloSerie" => "Cancers (Basel)" "fecha" => "2021" "volumen" => "13" "numero" => "5" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleSup">18</span>F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: Experience of a tertiary referral center" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.S. Elliott" 1 => "U. Metser" 2 => "M. De Perrot" 3 => "J. Cho" 4 => "P. Bradbury" 5 => "P. Veit-Haibach" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1259/bjr.20170814" "Revista" => array:6 [ "tituloSerie" => "Br J Radiol" "fecha" => "2018" "volumen" => "91" "numero" => "1086" "paginaInicial" => "1" "paginaFinal" => "5" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Delayed-phase enhancement for evaluation of malignant pleural mesothelioma on computed tomography: a prospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Patel" 1 => "L. Roshkovan" 2 => "S. McNulty" 3 => "E. Alley" 4 => "D.A. Torigian" 5 => "A.C. Nachiappan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cllc.2020.06.002" "Revista" => array:7 [ "tituloSerie" => "Clin Lung Cancer" "fecha" => "2021" "volumen" => "22" "numero" => "3" "paginaInicial" => "210" "paginaFinal" => "217" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32693945" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Thieke" 1 => "N.H. Nicolay" 2 => "F. Sterzing" 3 => "H. Hoffmann" 4 => "F. Roeder" 5 => "S. Safi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13014-015-0575-5" "Revista" => array:5 [ "tituloSerie" => "Radiat Oncol" "fecha" => "2015" "volumen" => "10" "paginaInicial" => "267" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26715491" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early response evaluation in malignant pleural mesothelioma by positron emission tomography with (18F) fluorodeoxyglucose" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G. Ceresoli" 1 => "A. Chiti" 2 => "P. Zucali" 3 => "M. Rodari" 4 => "R. Lutman" 5 => "S. Salamina" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2006.06.8999" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2006" "volumen" => "24" "paginaInicial" => "4587" "paginaFinal" => "4593" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17008700" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000004200000001/v1_202301120623/S2253808922000945/v1_202301120623/en/main.assets" "Apartado" => array:4 [ "identificador" => "7926" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000004200000001/v1_202301120623/S2253808922000945/v1_202301120623/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922000945?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 January | 1 | 2 | 3 |
2023 March | 3 | 5 | 8 |
2023 January | 1 | 2 | 3 |